Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Merck could pay up to $500mm to buy SmartCells

Executive Summary

Merck & Co. Inc. has agreed to buy privately held SmartCells Inc. (diabetes treatments) for up to $500mm, a price that includes cash up front as well as development, regulatory, and sales achievement earn-outs. (Strategic Transactions assumes 25% for the up-front payment--$125mm--and the rest in earn-outs.)
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition
    • Includes Earnout
    • Payment Includes Cash

Related Companies